Alector (ALEC) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Alector (ALEC) over the past year, gaining 129.0% versus a loss of 37.5%. Over five years, ALEC leads with a -91.8% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($236.3 million vs $217.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | IPSC |
|---|---|---|
| Share price | $1.95 | $1.31 |
| Market cap | $217.17M | $236.30M |
| 1-day change | +1.30% | +1.95% |
| YTD return | +23.08% | +28.64% |
| 1-year return | -37.46% | +128.98% |
| 5-year return | -91.76% | -93.37% |
| EPS (TTM) | $-1.09 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $3.04 |
| 52-week low | $1.09 | $0.435 |
| Distance from 52-week high | -42.79% | -57.07% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +69.67% | +263.98% |
| Average volume | 2.77M | 649.61K |
| Shares outstanding | 111.66M | 181.08M |
| Employees | 103 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed ALEC by 166.4 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
ALEC vs IPSC FAQ
Which is bigger, Alector or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $236.30M compared with $217.17M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or IPSC?
IPSC returned +128.98% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.